CANY
BPMC

Caxton Associates (New York)’s Blueprint Medicines BPMC Stock Holding History

Caxton Associates (New York)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,352
Closed -$255K – 463
2020
Q1 		$255K Buy
+4,352
New +$280K 0.05% 297

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caxton Associates (New York)'s BPMC Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Blueprint Medicines (BPMC) in Q2 2020, closing a stake of 4,352 shares — an estimated $255K sold.

Caxton Associates (New York) first reported a position in BPMC in Q1 2020 and held it in 1 quarter. The position peaked at $255K in Q1 2020. 234 funds tracked by Wall St. Rank hold BPMC as of Q2 2020.

  • Caxton Associates (New York) reported no remaining Blueprint Medicines position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,352 Blueprint Medicines shares in Q2 2020, an estimated $255K.
  • Caxton Associates (New York) first reported a position in Blueprint Medicines in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Blueprint Medicines position peaked at $255K in Q1 2020.
  • 234 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.